Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.

Abstract

Dimethyl fumarate is an orally bioavailable compound for the treatment of multiple sclerosis and psoriasis. A mechanism involving nuclear factor erythroid 2-like 2 activation has been proposed to account for its efficacy in multiple sclerosis. Here, we report that dimethyl fumarate inhibits expression of integrin α4 on circulating lymphocytes in experimental autoimmune encephalomyelitis mice and also on activated human Jurkat T cells in a manner distinct from nuclear factor erythroid 2-like 2 activation. Our results offer an alternative mechanism for the efficacy of dimethyl fumarate in multiple sclerosis.

• Authors: Yasuyuki Kihara, Aran Groves, Richard R Rivera, Jerold Chun
• Journal: Annals of clinical and translational neurology (Ann Clin Transl Neurol) Vol. 2 Issue 10 Pg. 978-83 (Oct 2015) ISSN: 2328-9503 [Print] United States
• PMID: 26478898 (Publication Type: Journal Article)